Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate the blood pressure reduction effect of valsartan/HCTZ 320/25 mg o.d. or 320/12.5 mg o.d. in patients with mild to moderate hypertension not adequately controlled with valsartan 320 mg monotherapy o.d. (MSDBP ≥90 mmHg and 110 mmHg at Visit 3) by testing the hypothesis that either valsartan/HCTZ 320/25 mg o.d. or valsartan/HCTZ 320/12.5 mg o.d. produces superior reduction in the mean sitting diastolic blood pressure (MSDPB) from baseline compared to valsartan 320 mg o.d alone
Critère d'inclusion
- Mild to moderate hypertension